Prashant Singh

PhD

Specializing In:

Genomics Epigenomics Next Generation Sequencing Single Cell Sequencing Spatial multi-omics Precision medicine Population genetics

Special Interests:

Multi-omics analysis of cancer initiation and progression

About Prashant Singh

Biography:

Dr. Prashant Singh joined Roswell Park Comprehensive Cancer Center in August 2015 as the Assistant Director of the Genomics Shared Resource (GSR) and the Department of Cancer Genetics & Genomics and he was promoted to Director of the GSR in 2019. 

Dr. Singh earned his doctoral degree in Biotechnology from the Institute of Genomics and Integrative Biology (IGIB) in Delhi, India and the University of Pune in Pune, India in 2010. After completing his PhD, he joined Roswell Park in 2010 as a post-doctoral fellow in the Department of Pharmacology & Therapeutics.

Dr. Singh utilizes multi-omics and interdisciplinary approaches to dissect cancer initiation and progression from a translational perspective, by combining insights from cell line, tumor models and patient material, and leveraging publicly available data. As the Director of the Genomics Shared Resource (GSR), he is responsible for scientific and operational leadership of the facility, and development and integration of cutting-edge genomic technologies.

Positions

Roswell Park Comprehensive Cancer Center

  • Director, Genomics Shared Resource
  • Assistant Member, Department of Cancer Genetics & Genomics

Background

Education and Training:

  • 2010 - PhD - Biotechnology, Institute of Genomics & Integrative Biology (IGIB), Delhi, and University of Pune, India

Professional Experience:

  • 2015 - Post-doctoral Associate, Department of Biochemistry, University at Buffalo, Buffalo, NY
  • 2010-2015 - Post-Doctoral Research Affiliate, Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • 2010 - Post-doctoral Associate, Department of Biostatistics, University at Buffalo, Buffalo, NY

Publications

Full Publications list on PubMed

Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, Zhang Y, Gomez EC, Morreale B, Senchanthisai S, Li J, Turowski SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, Dey P (2022). Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 40(2):153-167.e11

Long MD, Jacobi JJ, Singh PK, Llimos G, Wani SA, Rowsam AM, Rosario SR, Hoogstraat M, Linder S, Kirk J, Affronti HC, Bergman A, Zwart W, Campbell MJ, Smiraglia DJ (2021). Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer. Cell Rep. 37(11):110109

Long MD, Singh PK, Russell JR, Llimos G, Rosario S, Rizvi A, van den Berg PR, Kirk J, Sucheston-Campbell LE, Smiraglia DJ, Campbell MJ (2019). The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene. 38(3):421-444. PMC6336686

Singh PK, van den Berg PR, Long MD, Vreugdenhil A, Grieshober L, Ochs-Balcom HM, Wang J, Delcambre S, Heikkinen S, Carlberg C, Campbell MJ, Sucheston-Campbell LE (2017). Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-κB binding that is linked to immune phenotypes. BMC Genomics, 18(1):132. PMC5294817

Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli K, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ (2014). Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget, 5(3):824-40. PMC3996656